GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus

Author: Legakis, Ioannis

Source: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Volume 1, Number 3, November 2007 , pp. 193-201(9)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $104.88 plus tax (Refund Policy)

Abstract:

The gastrointestinal tract has a crucial role in the control of energy homeostasis through the action of multiple peptides known as incretins that act on distant target sites to promote the efficient uptake and storage of energy. In particular, GLP-1, an incretin hormone secreted from the intestinal mucosa in response to meal ingestion, is shown to augment the magnitude of meal-stimulated insulin secretion from islet β cells in a glucose-dependent manner and thus proved to be a novel candidate for treatment in patients with diabetes mellitus. This article reviews the biological actions of GLP-1 regulating glucose homeostasis, with an emphasis on mechanisms of action and the emerging therapeutic roles of GLP-1 analogues, and DPP-4 inhibitors for the treatment of diabetes mellitus.

Keywords: GLP-1 analogues; DPP-4 Inhibitors; diabetes mellitus

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187221407782409107

Publication date: 2007-11-01

More about this publication?

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.